---
title: "Chongqing Brewery released its semi-annual performance, with a net profit attributable to shareholders of 865 million yuan, a year-on-year decrease of 4.03%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253024977.md"
description: "Chongqing Brewery released its half-year performance for 2025, with revenue of 8.839 billion yuan, a year-on-year decrease of 0.24%; net profit attributable to shareholders of the parent company was 865 million yuan, a year-on-year decrease of 4.03%; net profit excluding non-recurring items was 855 million yuan, a year-on-year decrease of 3.72%; basic earnings per share were 1.79 yuan. Sales volume was 1.8008 million kiloliters, a year-on-year increase of 0.95%"
datetime: "2025-08-14T11:17:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253024977.md)
  - [en](https://longbridge.com/en/news/253024977.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253024977.md)
---

# Chongqing Brewery released its semi-annual performance, with a net profit attributable to shareholders of 865 million yuan, a year-on-year decrease of 4.03%

According to the Zhitong Finance APP, Chongqing Beer (600132.SH) disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 8.839 billion yuan, a year-on-year decrease of 0.24%; the net profit attributable to shareholders of the listed company was 865 million yuan, a year-on-year decrease of 4.03%; the net profit excluding non-recurring gains and losses was 855 million yuan, a year-on-year decrease of 3.72%; basic earnings per share were 1.79 yuan.

During the reporting period, the company achieved sales volume of 1.8008 million kiloliters, an increase of 0.95% compared to the same period last year

### Related Stocks

- [600132.CN](https://longbridge.com/en/quote/600132.CN.md)

## Related News & Research

- [One of America’s oldest beer brands discontinued after 177 years in US](https://longbridge.com/en/news/286978688.md)
- [Greene King sells Old Speckled Hen to Spanish beer giant](https://longbridge.com/en/news/286932205.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [15:56 ETCrownPoint Partners Facilitates Sale of Exceptional Emergency Center & Micro Hospital in Lubbock, TX](https://longbridge.com/en/news/287110768.md)